The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...

The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

GOV.UK states that the Medicines and Healthcare products Regulatory Agency (MHRA) "approved a product licence for the ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

AI-driven MRI solution, icobrain aria receives US FDA clearance for safer Alzheimer’s treatment: Boston Saturday, November 16, 2024, 16:00 Hrs [IST] icometrix, a g ...

F or the last eight years, Lakeland resident Natalie Aviles has participated in Walk to End Alzheimer’s Polk County. Each year brings new motivation that, one day, her friends, ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...